MedTrace Logo

A Survey Study to Assess the Accessibility of the Nerivio Device At School

NCT06180577 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 332

Last updated 2024-11-22

No results posted yet for this study

Summary

This is a retrospective survey-study to assess the accessibility, preference, and frequency of adolescents using Nerivio by itself, in combination with pharmacological medications, or not at all, in the school setting. The study population is prescribed Nerivio users, under the age of 18 years old, who have used the Nerivio device at least once. The study will be conducted electronically, and will include eligibility questions, an electronic informed consent form signed by the parent/legal guardian (e-ICF), an assent form signed by the adolescent patient (e-Assent), and an e-survey relating to the management of headaches due to migraine attacks. Participants will be recruited from Nerivio's userbase and will be compensated for their participation.

Conditions

  • Migraine in Children

Interventions

DEVICE

Nerivio

Nerivio is a prescribed Remote Electrical Neuromodulation (REN) device for treatment of migraine

Sponsors & Collaborators

  • Theranica

    lead INDUSTRY

Principal Investigators

  • Alit Stark Inbar, PhD · Theranica Bio-Electronics Ltd

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-01
Primary Completion
2024-05-01
Completion
2024-05-15
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06180577 on ClinicalTrials.gov